These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26490306)

  • 1. Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.
    Jackson CM; Kochel CM; Nirschl CJ; Durham NM; Ruzevick J; Alme A; Francica BJ; Elias J; Daniels A; Dubensky TW; Lauer P; Brockstedt DG; Baxi EG; Calabresi PA; Taube JM; Pardo CA; Brem H; Pardoll DM; Lim M; Drake CG
    Clin Cancer Res; 2016 Mar; 22(5):1161-72. PubMed ID: 26490306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
    Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
    Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
    Yamanaka R; Xanthopoulos KG
    DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
    Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
    J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination.
    Liau LM; Jensen ER; Kremen TJ; Odesa SK; Sykes SN; Soung MC; Miller JF; Bronstein JM
    Cancer Res; 2002 Apr; 62(8):2287-93. PubMed ID: 11956085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
    Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.
    Vanpouille-Box C; Diamond JM; Pilones KA; Zavadil J; Babb JS; Formenti SC; Barcellos-Hoff MH; Demaria S
    Cancer Res; 2015 Jun; 75(11):2232-42. PubMed ID: 25858148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
    Wu TY; Fleischmann WR
    J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
    Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
    Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
    Clark PA; Sriramaneni RN; Bates AM; Jin WJ; Jagodinsky JC; Hernandez R; Le T; Jeffery JJ; Marsh IR; Grudzinski JJ; Aluicio-Sarduy E; Barnhart TE; Anderson BR; Chakravarty I; Arthur IS; Kim K; Engle JW; Bednarz BP; Weichert JP; Morris ZS
    Radiat Res; 2021 Jun; 195(6):522-540. PubMed ID: 33826741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.
    Maciag PC; Seavey MM; Pan ZK; Ferrone S; Paterson Y
    Cancer Res; 2008 Oct; 68(19):8066-75. PubMed ID: 18829565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.
    Ashley DM; Faiola B; Nair S; Hale LP; Bigner DD; Gilboa E
    J Exp Med; 1997 Oct; 186(7):1177-82. PubMed ID: 9314567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
    Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
    Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis.
    Wang Q; Klinke DJ; Wang Z
    BMC Syst Biol; 2015 Jun; 9():27. PubMed ID: 26048402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.
    Singh M; Vianden C; Cantwell MJ; Dai Z; Xiao Z; Sharma M; Khong H; Jaiswal AR; Faak F; Hailemichael Y; Janssen LME; Bharadwaj U; Curran MA; Diab A; Bassett RL; Tweardy DJ; Hwu P; Overwijk WW
    Nat Commun; 2017 Nov; 8(1):1447. PubMed ID: 29129918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.